MedPath

Biojiva LLC

🇺🇸United States
Ownership
Private
Employees
-
Market Cap
-
Website

Clinical Trials

2

Active:0
Completed:1

Trial Phases

2 Phases

Phase 1:1
Phase 2:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Phase 1
1 (50.0%)
Phase 2
1 (50.0%)

A Phase 1/2 Study of the Safety and Efficacy of BRX011 Oral Administration Once Daily in Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Phase 1
Not yet recruiting
Conditions
Geographic Atrophy
Interventions
Drug: BRX011
Drug: Placebo
First Posted Date
2025-06-19
Last Posted Date
2025-06-26
Lead Sponsor
Biojiva LLC
Target Recruit Count
152
Registration Number
NCT07029945

RT001 in Amyotrophic Lateral Sclerosis

Phase 2
Completed
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Drug: Placebo
First Posted Date
2021-02-21
Last Posted Date
2025-07-01
Lead Sponsor
Biojiva LLC
Target Recruit Count
43
Registration Number
NCT04762589
Locations
🇪🇪

University of Tartu, Tartu, Estonia

🇱🇻

Riga Stradins Universtiy, Riga, Latvia

🇳🇱

UMC Utrecht, Utrecht, Netherlands

and more 1 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.